Home » Stocks » BCYC

Bicycle Therapeutics PLC (BCYC)

Stock Price: $19.69 USD -0.98 (-4.74%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 85.32M
Revenue (ttm) 11.82M
Net Income (ttm) -37.98M
Shares Out 19.43M
EPS (ttm) -4.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $19.69
Previous Close $20.67
Change ($) -0.98
Change (%) -4.74%
Day's Open 21.00
Day's Range 19.66 - 21.68
Day's Volume 76,979
52-Week Range 7.68 - 21.68

More Stats

Market Cap 85.32M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 19.43M
Float n/a
EPS (basic) -1.59
EPS (diluted) -4.99
FCF / Share -0.37
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 275,139
Short Ratio 5.00
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.22
PB Ratio 3.85
Revenue 11.82M
Operating Income -39.67M
Net Income -37.98M
Free Cash Flow -7.20M
Net Cash 134.77M
Net Cash / Share 31.10
Gross Margin -99.29%
Operating Margin -335.49%
Profit Margin -321.30%
FCF Margin -60.88%
ROA -17.33%
ROE -37.08%
ROIC -399.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(40.73% upside)
Current: $19.69
Target: 27.71
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth93.4%246.41%-
Gross Profit13.807.142.06
Operating Income-26.30-21.75-16.21
Net Income-30.61-21.85-16.26
Shares Outstanding11.050.440.33
Earnings Per Share-2.77-49.78-48.81
Operating Cash Flow-28.61-26.08-1.42
Capital Expenditures-1.56-1.19-1.11
Free Cash Flow-30.17-27.26-2.53
Cash & Equivalents92.1263.3867.66
Total Debt1.25--
Net Cash / Debt90.8763.3867.66
Book Value93.20-69.83-47.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bicycle Therapeutics PLC
Employees 81
CEO Kevin Lee

Stock Information

Ticker Symbol BCYC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BCYC
IPO Date May 23, 2019


Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.